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Exhaustive research to identify genetic disorders in the CFTR gene leads to the de-
tection of constantly increasing number of sequence variations of unknown clinical
signiﬁcance (UV), specially with the event of new sequencing technologies. In 2009
the collaboration of 9 French specialized laboratories led to collect molecular and
minimal clinical data not only in CF but also in CFTR-RD patients and “compound
heterozygous” unaffected parents. These manually-curated data are integrated into
a database: UMD-CFTR-France. Currently, it contains genotypes and haplotypes of
3473 subjects: 68.7% CF, 24.16% CFTR-RD, 7.14% analysed in another context
(NBS, fetal bowel anomalies . . . ). 581 different variants have been reported (12507
entries): 62.3% disease-causing mutations, 8.4% non-pathogenic alterations and
29.3% UVs (mostly rare missense variations). To assess UV pathogenicity we have
worked on a classiﬁcation (UV1 to 4) based on frequency, ﬁrst description in
the Cystic Fibrosis Mutation Database, familial segregation, results of in silico
studies (e.g SIFT, PPH2, HSF, MaxEnt) and data from the literature (epidemiology,
functional studies). The collection of data from the general population is in process.
Pooling of these data should signiﬁcantly help the interpretation of rare variants,
the analysis of correlations between genotypes/haplotypes and phenotypes, and
participate in the improvement of diagnosis and genetic counseling.
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Molecular diagnosis of cystic ﬁbrosis and CFTR-related disorders led to the
worldwide identiﬁcation of nearly 1900 sequence variations in the CFTR gene.
Except for a set of 21 frequent disease-causing mutations, the majority of them
are private point mutations or microinsertions/deletions. Thus, it is difﬁcult to
establish a priori the effect of rare intronic, synonymous or missense variants on the
function of the encoded protein and therefore their involvement in the disease, which
directly impacts genetic counselling. In this context we developed a model for the
classiﬁcation of variants of unknown clinical signiﬁcance according to international
guidelines (Clinical Molecular Genetics Society, 2007) and speciﬁcally adapted to
the CFTR gene. We built a decision algorithm and deﬁned a rating scale for a series
of major and minor criteria, including thorough in silico and in vitro functional
studies at mRNA and protein level. We ﬁrst applied this model to 15 unclassiﬁed
variants (10 intronic and 5 exonic) found in our cohort of patients. Six variants
were classiﬁed as probably non-pathogenic considering their impact on splicing
while nine, including 3 apparent missense variants, were considered as likely or
probably pathogenic. This preliminary study was designed to test and reﬁne our
model, which is being validated on a wide range of CFTR variants. Finally, our
data provide strong arguments to select variants that require transcript analysis in
nasal epithelial cells to conﬁrm in vitro results and establish genotype/phenotype
correlation.
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Objectives: Cystic Fibrosis (CF) is one of the most frequent indications for preim-
plantation genetic diagnosis (PGD), allowing couples at-risk of bearing offspring
with CF to reproduce without fear of having an affected child. We present here a
ﬂuorescent multiplex PCR approach for PGD for CF as well as the results of our
large experience over a 8-year period.
Methods: In order to provide a reliable PGD procedure for CF, we have developed
an efﬁcient ﬂuorescent multiplex PCR protocol allowing the simultaneous analysis
of the p.F508del mutation together with eight polymorphic sequences either located
within or on each side of the CFTR gene. We have applied this PCR protocol in
66 PGD cycles from 32 couples, including
i. couples with both members heterozygous for a severe or large spectrum CFTR
gene mutation (n = 23),
ii. a CF-affected member (n = 4) and
iii. CBAVD in males (n = 5).
All (but one) cycles with embryo biopsy resulted in embryo transfer. One to 3
genetically unaffected embryos (healthy or carrier) were selected for transfer in 47
cycles resulting in 17 clinical pregnancies (36.2% per transfer). Sixteen babies were
born and no child was diagnosed with CF after the newborn screening test that is
systematically performed in France for CF. One pregnancy is still ongoing.
Conclusion: These results show that PGD is presently a practical approach for
prevention of CF in affected families. The multiplex PCR protocol we have
developed is higly reliable enabling an accurate diagnosis in all cases. It may be
applicable to all the couples requesting PGD for CF analysed in our PGD program,
broadening the range of prenatal testing options for these families.
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The aim of this study is to show that historical data can help understanding the
spreading process of CFTR mutations on a speciﬁc area that is particularly affected
by the disease.
The population at the root of this study is composed of patients clinically diagnosed
as suffering from CF and having lived in Brittany (705 ind). Their ancestry was
traced back and brought together more than 250 000 kinspeople.
The carriers who share the same CF mutation are kindreds. The mapping of their
common ancestors’ living places show a differential distribution, depending on
speciﬁc CF mutations.
At the ancestors’ level, we observed marital unions at an early age, particularly
women’s, and frequent remarriage, particularly men’s. In addition, married couples
were proliﬁc, thus allowing more genetic transmissions. The geographical stability
that prevailed at the time of the wedding does not seem to produce genetic diversity.
Moreover, we reckoned that in terms of life expectancy there might be some
selective advantage to being a healthy carrier.
Inbreeding was in no way a key factor in this study. Only 0.8% were born from
ﬁrst or second cousin unions.
At the ancestors’ level, we must go back to the 7th generation to see a higher pro-
portion of close kinship. Therefore, more often than consanguinity, it is endogamy
which tends to carry on a certain degree of genetic homogeneity.
CF frequency of occurrence and its Breton distribution today can be accounted
for by the presence of a harmful gene combined with high fertility, a relatively
settled population with a limited availability of possible partners, and the selective
advantage this harmful gene was for healthy carriers.
